Progress in the Application of Peptide Vaccines in the COVID-19
DOI:
https://doi.org/10.62051/km9mnm66Keywords:
COVID-19; peptide vaccine; S protein; CoVac-1 vaccine.Abstract
A brand-new coronavirus dubbed COVID-19 epidemic broke out in the winter of 2019 and quickly swept the globe. Additionally, the pandemic's high mortality rate and high infection have prompted sustained scientific efforts to treat the illness. Backing the history of the virus, vaccine development is the most effective method to mitigate this urgent public issue. Pharmaceutical firms from nations including China, the United States, and Russia subsequently started doing research on vaccine development. While Pfizer and Monard in the US utilize mRNA genetic vaccines, China uses inactivated vaccines and viral vector vaccines. As a result of the difficult inactivated vaccine manufacture procedure and the issue of toxicity rebound, there is also a chance that genetic vaccines will mate with host genes. It is thought that the creation of peptide vaccines will deal with these two problems. Peptide vaccines are therefore seen to be the safest, and they may be employed not only for preventative immunization but also for the treatment of solid malignancies. Clinical studies for peptide vaccines are underway. But because peptide vaccinations are quickly broken down by cells, their drug carriers play a crucial role as well. This article will outline the selection of the protein sequence for the COVID-19 peptide vaccine as well as the development of its tests.
Downloads
References
Mohammad KO, Lin A, Rodriguez JBC. Cardiac Manifestations of Post-Acute COVID-19 Infection. Curr Cardiol Rep. 2022 Dec; 24 (12): 1775 - 1783.
Goyal PK, Mohammed TO, Mahmoud A, et al. Nguyen CV. COVID-19 infection leading to acute pustular dermatoses. Arch Dermatol Res. 2023 May; 315 (4): 685 - 697.
Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020 May 1; 70 (9): 311 - 322. English, Spanish.
Fernandes Q, Inchakalody VP, Merhi M, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022 Dec; 54 (1): 524 - 540.
Gupta, A., Madhavan, M.V., Sehgal, K. et al. Extrapulmonary manifestations of COVID-19. Nat Med 26, 1017 – 1032 (2020).
Kaul R, Devi S. Coronavirus - A Crippling Affliction to Humans. Recent Pat Biotechnol. 2022 Aug 3; 16 (3): 226 - 242.
Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005 Dec; 69 (4): 635 - 64.
Matta J, Wiernik E, Robineau O, Carrat F, et al., Relations et Inégalités Sociales en Population Générale Pendant la Crise COVID-19–Sérologie (SAPRIS-SERO) Study Group. Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results with Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Intern Med. 2022 Jan 1; 182 (1): 19 - 25.
Nelde A, Rammensee HG, Walz JS. The Peptide Vaccine of the Future. Mol Cell Proteomics. 2021; 20: 100022.
O'Neill CL, Shrimali PC, Clapacs ZE, et al. Peptide-based supramolecular vaccine systems. Acta Biomater. 2021 Oct 1; 133: 153 - 167.
Zagorski K, Pandey K, Rajaiah R, et al. Peptide Nanoarray Scaffold Vaccine for SARS-COV-2 and Its Variants of Concerns. Res Sq [Preprint]. 2022 Jan 24: rs. 3. Rs - 1206402.
TopuzoĞullari M, Acar T, Pelİt Arayici P, et al. An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. Turk J Biol. 2020 Jun 21; 44 (3): 215 - 227.
He Y, Hong C, Fletcher SJ, Berger AG, et al. Peptide-Based Cancer Vaccine Delivery via the STINGΔTM-cGAMP Complex. Adv Healthc Mater. 2022 Aug;11 (15): e2200905.
Negahdaripour M, Golkar N, Hajighahramani N, et al. Harnessing self-assembled peptide nanoparticles in epitope vaccine design. Biotechnol Adv. 2017 Sep; 35 (5): 575 - 596.
Heitmann JS, Bilich T, Tandler C, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature. 2022 Jan; 601 (7894): 617 - 622.
Muchowska KB, Moran J. Peptide synthesis at the origin of life. Science. 2020 Nov 13; 370 (6518): 767 - 768.
Information on: https://www.phgfoundation.org/briefing/rna-vaccines.
Buonaguro L, Tagliamonte M. Peptide-based vaccine for cancer therapies. Front Immunol. 2023 Aug 16; 14: 1210044.
Li M, Wang H, Tian L, Pang Z, et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022 May 3; 7 (1): 146.
Hadj Hassine I. Covid-19 vaccines and variants of concern: A review. Rev Med Virol. 2022 Jul; 32 (4): e2313.
Al Kaabi N, Zhang Y, Xia S et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021 Jul 6; 326 (1): 35 - 45.
Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015 Nov 10; 217: 345 - 51.
Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022 Feb; 28 (2): 202 - 221.
S.A. MEO1, I.A. BUKHARI2, et al, COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines European Review for Medical and Pharmacological Sciences 2021; 25: 1663 - 1669.
Khetarpal N, Khanna I. Dengue Fever: Causes, Complications, and Vaccine Strategies. J Immunol Res. 2016; 2016: 6803098.
Wilder-Smith A. Dengue vaccine development: status and future. Bundesgesundheitsblatt Gesundheitsforschung Gesundheit Schutz. 2020 Jan; 63 (1): 40 - 44.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
